ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
The ACYP2-driven c-Myc/PARP1 signaling axis defines a critical pathway driving TMZ resistance and represents a translationally actionable target for therapeutic intervention in GBM.
Authors
- Mengjun Sui (ORCID: https://orcid.org/0009-0009-2188-0872)
- Mengdan Li
- Y. Zhang
- Gang Li (ORCID: https://orcid.org/0009-0002-1292-1723)
- Jinjin Li (ORCID: https://orcid.org/0000-0001-9947-6858)
- Penggao Dai (ORCID: https://orcid.org/0000-0001-6211-4634)
- Qing Cai (ORCID: https://orcid.org/0000-0003-0304-5151)
- Zhiwei Sun
Institutions
- Northwest University (CN)
- Sugen Life Sciences (India) (IN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Tang Du Hospital (CN)
- Xi'an Jiaotong University (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Molecular Cancer Research
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1158/1541-7786.mcr-25-0423
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00